H<sub>2</sub>O<sub>2</sub>-responsive biodegradable nanomedicine for cancer-selective dual-modal imaging guided precise photodynamic therapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 30953845.
- Also identified by DOI 10.1016/j.biomaterials.2019.03.042.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
A tumor-related stimuli-activatable and biodegradable nanoplatform for tumor-selective imaging and effective photodynamic therapy (PDT) towards precision medicine is highly desirable but still greatly challenging. Here, we developed a novel H<sub>2</sub>O<sub>2</sub>-activatable and biodegradable nanomedicine (BSA-MBPB) by encapsulation of a single newly synthesized pro-photosensitizer (MBPB) with its photoactivity completely annihilated within bovine serum albumin (BSA) to achieve imaging-guided tumor-targeted effective PDT. BSA-MBPB can be decomposed and activated by H<sub>2</sub>O<sub>2</sub> to not only produce the clinical photosensitizer methylene blue to recover its fluorescent, photoacoustic and photosensitizing properties for dual-modal imaging and cytotoxic singlet oxygen (<sup>1</sup>O<sub>2</sub>) generation, but also to simultaneously produce a GSH-depleting adjuvant quinone methide to boost the <sup>1</sup>O<sub>2</sub> yield, thus strengthening the efficacy of PDT. BSA-MBPB allows for highly efficient and accurate PDT without major side effects, offering potential as the next-generation nanomedicine towards clinical practice of precise PDT.
Medical subject headings
- Hydrogen Peroxide
- Nanomedicine
- Photochemotherapy